Biotech's Hottest Backdoor Into Wall Street Is Running Out of Keys
Biotech startups are ditching the traditional IPO and flooding into reverse mergers at record pace, with roughly two dozen deals and $2 billion in financing so far in 2026. But the supply of clean shell companies is running thin, and regulators are tightening the screws.
The Line Outside the Back Door
When the front entrance is locked, you find another way in. That's exactly what dozens of biotech startups have decided to do in 2026.
The traditional IPO market, once the golden ticket for private drug developers wanting to go public, has been anything but welcoming. In 2025, there were only about 10 to 11 biotech IPOs all year, the weakest showing in over a decade. The second quarter of 2025 saw literally zero.
So biotechs did what any resourceful startup would do. They stopped waiting in line and started sneaking through the back door: reverse mergers.
What's a Reverse Merger, and Why Should You Care?
Think of it like buying an old storefront on Main Street instead of building from scratch. A reverse merger lets a private company take over a publicly listed "shell company" (often a failed or near-empty public biotech) and inherit its stock exchange listing. No IPO roadshow. No months of SEC paperwork. Just a deal, some financing, and suddenly you're trading on Nasdaq.
These transactions used to carry a stigma. They were the dollar-store version of going public, dismissed by serious investors as desperate or sketchy. But the class of 2026 is rewriting that reputation.
Roughly two dozen reverse mergers involving biotechs have been announced so far this year, with about 19 completed or planned. That pace is closing in on the number of traditional biotech IPOs. Cooley partner Rama Padmanabhan has called this a "second generation" of reverse mergers, supported by a more robust financing market and credible investors willing to back the deals.
The Deals Are Getting Bigger
This isn't a fringe phenomenon anymore. The money flowing into these transactions is serious. About $2 billion in private financing has accompanied biotech reverse mergers announced so far in 2026.
Look at some of the headline deals:
Avere Therapeutics merged with NextCure in July, bringing a concurrent investment and a focus on inflammation.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
$320 million
Boundless Bio paired with Serapha Bio in an all-stock deal backed by a $230 million placement.
Avenzo Therapeutics, a clinical-stage oncology company working on CDK2/CDK4 inhibitors and bispecific antibody-drug conjugates, took over Rallybio's listing with $215 million in financing.
Ambros Therapeutics announced the most recent deal in August, merging with Werewolf Therapeutics and raising a $150 million PIPE (private investment in public equity, essentially a big fundraise attached to the deal).
These aren't garage-sale transactions. They look more like mini-IPOs, complete with institutional backing and nine-figure financing rounds.
The Shell Game Gets Crowded
Here's where things get interesting. When everyone wants to use the same shortcut, the shortcut gets congested.
Deal experts are now asking a question that would have sounded absurd two years ago: are there enough quality shell companies to go around? The raw number of failed or near-empty public biotechs might seem adequate, but "available" and "usable" are two very different things.
Many potential shells come with baggage: old lawsuits, messy balance sheets, complicated capital structures, or retained liabilities that no acquirer wants to inherit. Think of it like house hunting in a hot market. There are plenty of listings, but half of them have foundation problems, and the other half are overpriced. The supply of clean shells, ones without legal headaches or structural nightmares, is genuinely tight.
Making matters worse, the SEC has raised the bar for these deals. New rules (particularly Rule 145a) treat many reverse mergers involving shell companies as securities sales, requiring more disclosure and creating more liability. Forward-looking projections, once a selling point for biotech SPACs, are now riskier to include because safe-harbor protections no longer apply to blank-check companies. The regulatory framework keeps tightening rather than loosening; Nasdaq even narrowed some listing rules for certain de-SPAC transactions in late 2025.
All of this means the costs and complexity of reverse mergers are climbing, even as demand soars.
Why Not Just Wait for the IPO Window?
Fair question. And the answer is: some companies can't afford to.
The 2026 IPO market has improved compared to 2025's wasteland. Goodwin and other advisors see a growing backlog of companies ready to list, supported by better biotech index performance and improving capital-markets conditions. But the recovery is selective. Investors want later-stage companies with strong clinical data, not early-stage moonshots running on optimism and a PowerPoint deck.
For clinical-stage biotechs that need capital now, waiting another six months for the IPO window to widen isn't a strategy; it's a gamble. Reverse mergers offer something the IPO process can't: certainty. You negotiate a deal, lock in your financing through a PIPE, and get to the public markets on a predictable timeline. Roughly 45 out of 55 tracked reverse-merger deals from 2023 to 2026 included PIPE financing, showing just how standardized this playbook has become.
Compare that to an IPO, where your pricing depends on the market's mood the week you go public. After watching peers lose a third of their value post-listing, you can see why founders are choosing the known quantity.
The Bigger Picture
Last year, only 10 reverse mergers closed across all of 2025. This year, we're on pace to more than double that. The acceleration tells a story about something deeper than just a trendy deal structure.
Biotech's public-market plumbing is being rewired in real time. The IPO drought of 2024 and 2025 didn't just delay listings; it created an entire ecosystem of alternative routes. Reverse mergers went from Plan B to Plan A for a meaningful slice of the industry. The question now is whether this pace is sustainable, or whether the shrinking pool of quality shells and rising regulatory costs will force yet another pivot.
For investors, the key takeaway is straightforward: pay attention to what these newly public companies actually look like. A slick reverse merger with a $200 million PIPE isn't inherently better or worse than a traditional IPO. What matters is the science, the data, and the balance sheet that emerges on the other side.
The back door is open. For how long is anyone's guess.
Clinical & Regulatory
4 min read
BridgeBio Just Abandoned the Biggest Prize in KRAS Cancer
BridgeBio Oncology pulled its lead KRAS drug out of the lucrative first-line lung cancer race, shrinking from a 200,000-patient opportunity to roughly 50,000. The stock dropped 24% in a single session, and the competitive fallout is just getting started.
